Skip to content
Open access

Results of a prospective, observational, multicenter study of patients with hypertension and chronic kidney disease in the Russian Federation (PRIORITY-CKD)

Sep 2026 · Russian Journal of Cardiology · 0 citations · 30 references

Abstract

Aim. To assess the incidence of chronic kidney disease (CKD) in adult patients with hypertension (HTN) and markers of CKD without concomitant diabetes and symptomatic heart failure, as well as to describe the clinical and demographic characte­ristics and treatment options in the overall cohort and a subgroup with verified CKD. Material and methods. PRIORITY-CKD is a multicenter, observational, prospective study with a retrospective analysis of patients with hypertension and markers of CKD in the Russian Federation. The study design has been described in detail previously. Results. The analytical cohort included 9914 patients. The diagnosis of CKD was confirmed in 8430 (85%) patients with HTN and CKD markers during the study as follows: 3795 (38,3%) at Visit 1 and 4635 (46,8%) at Visit 2. The estimated glomerular filtration rate was used as diagnostic criteria in 8406 (97,4%) cases. Albuminuria/proteinuria and a combination of markers were used in 13 (0,2%) and 11 (0,1%) patients, respectively. In the overall cohort and the subgroup with verified CKD, women predominated, the median duration of hypertension was similar and amounted to 10 years. More than half of the patients had stage III hypertension and the very high cardiovascular risk ca­tegory. A high frequency of metabolic risk factors (overweight, abdominal obesity, dyslipidemia) and coronary artery disease (33%/34,9% in the two cohorts, respectively) was observed. Uncontrolled blood pressure (BP) (systolic BP ≥140 and/or diastolic BP ≥90 mm Hg while receiving antihypertensive therapy (AHT)) and signs of AHT resistance were detected in 36,0% and 6,0% of patients in the overall cohort, respectively, and in the same proportion of patients in the CKD subgroup. Combination AHT was received by 72,3% of patients in the study cohort after Visit 1. After CKD diagnosis was confirmed, sodium-glucose cotransporter type 2 inhibitors were prescribed in 31,1% of cases. Conclusion. In the Russian population, CKD was confirmed in 85% of patients with HTN and CKD markers. Albuminuria/proteinuria was assessed extremely rarely. A high frequency of uncontrolled HTN, a significant burden of metabolic risk factors, and cardiovascular disease were observed in the overall cohort and the CKD subgroup. The incremental use of renoprotective therapy after verification of the CKD diagnosis was insufficient.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.